Skip to product information
1 of 1

  • Images are for illustration purposes only
  • Gphc Registered
  • Join over 100k customers
  • Fixed prices and no subscriptions
  • Discreet next day delivery.
  • Free shipping on all orders over £50

Burt's Bees mama Leg & Foot Cream (100 ml)

Burt's Bees mama Leg & Foot Cream (100 ml)

  • 1. Ozempic®️-equivalent therapy now available for weight management
  • 2. Average weight loss of 17%, with 1 in 3 patients achieving over 20%
  • 3. May help reduce osteoarthritis-related pain
  • 4. Wegovy®️ is not expected to impact the effectiveness of oral contraceptives
  • 5. Supports cardiovascular risk reduction
  • 6. Over 22 million patients treated with semaglutide-based therapies since 2018

We’re proud to offer fast and discreet delivery for all our medicines & treatments.

Price Checker

Regular price £13.49
Sale price £13.49
Sale Sold out
  • Lowest price guarantee
  • Includes FREE private prescription
View full details

Burt’s Bees Mama Leg & Foot Cream provides relief to tired legs and feet through its natural ingredients which are specifically designed for expectant mothers and new mothers. The nourishing cream provides a refreshing cooling sensation while deeply hydrating the skin through its natural ingredients peppermint oil and rosemary extract and coconut oil. The 100% natural formula of this product absorbs quickly into skin to provide softness and light invigoration while moisturizing expectant mothers' swollen feet and aching legs. The botanical blend provides daily use safety while remaining free from phthalates parabens petrolatum and SLS.

Key Benefits

The product provides cooling relief and soothing and moisturizing benefits to tired legs and feet. The product contains peppermint oil and rosemary extract. The product has been tested by dermatologists and contains 100% natural ingredients. The product is safe for use during pregnancy and after childbirth. The product contains no harsh chemicals or synthetic fragrances. This gentle yet effective cream is designed for mamas who need a little comfort.

Patient Information Leaflet

Important - Before taking any medication, it is always important to read the Patient Information Leaflet (PIL)

Written and reviewed by our qualified team

GPhC Number: 2233073
Tarun Kumar

Reviewed by:

Tarun Kumar

Superintendent/ Clinical Lead

📖 Find out more about our team of medical content authors and how we ensure the accuracy of our content with our content guidelines.

Content last updated: 31 Mar 2025

We’re a safe and
regulated UK service

Registered Pharmacy Badge

Lowest Price Guarantee

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

100% discreet packaging

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

Agent

Need help?
Talk to our friendly experts now

How our service works

Service Setup

Service setup

Discreet Packaging

Discreet packaging

Express Delivery

Express delivery

Comparison of Weight Loss Injectables

Features

Mounjaro®

Injectable Pen

Wegovy®

Injectable Pen

Saxenda®

Injectable Pen

Active Ingredient Tirzepatide Semaglutide Liraglutide
Mechanism of Action GLP-1 and GIP receptor agonist GLP-1 receptor agonist GLP-1 receptor agonist
Administration Weekly injection Weekly injection Daily injection
Dosage Varies by patient, typically starting low Varies, typically starting at 0.25 mg Varies, starting at 0.6 mg
Effect on Appetite Significantly reduces appetite and cravings Reduces appetite and increases satiety Reduces appetite and increases satiety
Average Weight Loss Up to 20% body weight reduction Up to 15% body weight reduction Significant weight reduction
Side Effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation Nausea, diarrhoea, constipation, hypoglycemia
Approval FDA-approved for weight loss FDA-approved for weight loss FDA-approved for weight loss
Suitable For Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities